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Introduction {#sec1}
============

Viruses within the *Flavivirus* genus represent an overwhelming disease burden to humans, in worst cases causing either encephalitis or hemorrhagic fever with mortality rates up to 50% ([@bib21]). The success of flaviviruses is in large part associated with transmission by arthropod vectors, either mosquito borne, represented by dengue virus (DENV), West Nile virus (WNV), and Zika virus, or tick borne, including tick-borne encephalitis virus (TBEV), Omsk hemorrhagic fever virus, Kyasanur Forest disease virus (KFDV), and Powassan virus (POWV). No specific antiviral therapy is available for the millions of individuals infected with flaviviruses each year. We rationalize that to develop desperately needed drugs and vaccines to treat and prevent flavivirus infections, we need to better understand how flaviviruses infect cells and cause disease.

The flavivirus chymotrypsin-like serine protease, nonstructural 3 (NS3), is an ideal target for broad-spectrum antiviral development ([@bib24]). NS3 is relatively conserved between the flaviviruses and is essential for virus replication, functioning to cleave the viral polyprotein into mature individual proteins through a well-characterized enzymatic function ([@bib22], [@bib31]). Mutant flaviviruses with an inactive NS3 protease are unable to generate infectious virions ([@bib7]). Despite substantial effort and resources directed toward the design of NS3 protease inhibitors, there has only been limited success and no compound has reached the clinical trial stage ([@bib6]). Innovative discovery approaches seek to expand potential drug targets by identifying protein-protein interactions necessary for viral protein function during infection ([@bib14]). We reasoned here that the identification of host proteins that interact with NS3 may direct us toward methods to inhibit NS3, either by modeling antiviral drugs from host antiviral interactions with NS3, or by identifying host proteins that NS3 uses during infection.

Bioinformatic analysis of the TBEV polyprotein revealed a potential interaction with the host protein tumor necrosis factor receptor-associated factor 6 (TRAF6). TRAF6 is an important antiviral intracellular molecule for the interleukin-1(IL-1)/Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I) signaling pathways ([@bib19], [@bib42], [@bib45]). It functions by linking innate immune receptor engagement to activation of protein kinase complexes, culminating in activation of transcription factors including nuclear factor-κB (NF-κB) and activator protein-1 ([@bib41]). TRAF6 is an E3 ubiquitin ligase and binds substrate proteins through a conserved TRAF6 binding motif (TBM). A canonical TBM is formed from the amino acid sequence P-X-E-X-X-Ac/Ar (X representing any amino acid, Ac/Ar representing either an acidic or aromatic residue) ([@bib8]). TRAF6 has also been shown to bind to non-canonical TBMs that have alternative amino acids sequences ([@bib15], [@bib27], [@bib30], [@bib37]).

In this study, we discovered and experimentally validated a TBM in NS3 of tick-borne flaviviruses (TBFVs), which is not present in mosquito-borne flaviviruses (MBFVs). The protein interaction between TRAF6 and NS3 is disrupted by site-directed mutagenesis, and, in the context of the full TBFV genome, the mutation results in virus attenuation. We found that TBM mutation within NS3 impairs the expression of the mature, active form of the viral protease (NS3pro). NS3pro is only produced during infection by autoproteolytic cleavage and is essential for flavivirus replication. Our data suggest that TRAF6 actively participates in the TBFV replication cycle to maintain NS3pro expression, possibly through protein stabilization or protease activation. Thus TRAF6\'s structural and functional contributions to NS3pro maturation, in addition to the TRAF6-NS3 complex, serve as potential therapeutic targets that should be further explored for treatment of the TBFVs.

Results {#sec2}
=======

TBFV, but Not MBFV, NS3pro Interacts with TRAF6 {#sec2.1}
-----------------------------------------------

To investigate the cellular factors regulating TBFV replication, we performed a bioinformatic analysis of the TBEV polyprotein using the Eukaryotic Linear Motif Resource for Functional Sites in Proteins ([@bib9]). Our primary screen revealed a solitary putative canonical TBM, P-F-E-V-K-D (TBM1), located within the protease domain of NS3 (NS3pro) between residues 17 and 22 ([Figure 1](#fig1){ref-type="fig"}A). Further analysis of NS3pro identified a non-canonical putative TBM, P-G-E-L-L-L (TBM2), at residues 115--120, in which the terminal amino acid of the consensus sequence is neither acidic nor aromatic ([Figure 1](#fig1){ref-type="fig"}A) ([@bib15]). Sequence alignment of NS3pro from other flaviviruses showed that the two putative TBMs are highly conserved among TBFVs ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A--S1C), with the exception of the evolutionarily isolated POWV ([@bib17]). TBM2 was not present in NS3 of POWV. Furthermore, we did not identify TBM1 or TBM2 in any MBFV ([Figure 1](#fig1){ref-type="fig"}A), suggesting a possible unique and specific interaction between TBFVs and TRAF6.Figure 1LGTV NS3pro Interacts with TRAF6(A) Sequence alignment of tick- or mosquito-borne flavivirus NS3pro. Putative TBMs are underlined, and anchor amino acids are highlighted in blue. Conserved residues of the catalytic triad are highlighted in red.(B) Representative images of colocalization of LGTV NS3 and TRAF6. HEK293 cells expressing GFP or TRAF6-GFP were infected with LGTV at an MOI of 1. Cells were processed at 24 hpi, stained with anti-NS3 (red) and anti-GFP (green) antibodies, and visualized by confocal microscopy. Nuclei were stained with DAPI (blue); scale bar (white solid line), 10 μM. Yellow represents co-localized proteins. White box indicates area of enlargement in inset panel; inset scale bar (white solid line), 5 μM. White arrowhead indicates a distinct TRAF6 punctum observed in uninfected cells.(C) CoIP of LGTV NS3 and endogenous TRAF6 during infection. HEK293 cells were infected with LGTV at an MOI of 1. Cell lysates were prepared at 48 hpi, incubated with either anti-NS3 or control IgY antisera, and precipitated with PrecipHen beads. Samples were analyzed by immunoblot with the indicated antibodies. Results representative of two independent experiments.(D) CoIP of LGTV NS3 and TRAF6. HEK293 cells expressing TRAF6-GFP were infected with LGTV or KUNV at an MOI of 10. Cell lysates were immunoprecipitated with anti-GFP antibody and protein-A-conjugated agarose beads at 48 hpi. Samples were analyzed by immunoblot with the indicated antibodies. Results representative of three independent experiments.(E) CoAP of recombinant LGTV NS3 constructs with TRAF6. HEK293 cells were transfected with 2 μg of each indicated plasmid. Cell lysates were pulled down using streptavidin-conjugated beads at 24 h post-transfection, and eluted proteins were analyzed by immunoblot with indicated antibodies. Results representative of three or more independent experiments. POI, protein of interest.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Based on our bioinformatics results, we first examined a potential interaction between TBFV NS3 and TRAF6 using immunofluorescent microscopy. For this purpose, human embryonic kidney (HEK) 293 cells expressing either GFP or a GFP-tagged TRAF6 (TRAF6-GFP) were infected with Langat virus (LGTV), a prototypical member of the TBEV serogroup. Confocal analyses revealed strong co-localization of LGTV NS3 and TRAF6 proteins at 24 h post-infection (hpi) ([Figure 1](#fig1){ref-type="fig"}B). We also observed a change in the cellular distribution of TRAF6-GFP, from discrete puncta in uninfected cells to a large perinuclear aggregate during infection ([Figure 1](#fig1){ref-type="fig"}B). To validate the confocal results, we took a biochemical approach and preformed a co-immunoprecipitation (coIP) of endogenous TRAF6 with LGTV NS3. HEK293 cells were infected with LGTV, and at 48 hpi, anti-NS3 antibody was used to precipitate LGTV NS3. We were able to pull down endogenous TRAF6 with LGTV NS3 ([Figure 1](#fig1){ref-type="fig"}C). In addition, we tested the specificity of TBFV NS3 to interact with TRAF6 by preforming a coIP with HEK293 cells expressing TRAF6-GFP. Cells were either infected with LGTV or Kunjin virus (KUNV), an MBFV that lacks TBM1 and TBM2 ([Figure 1](#fig1){ref-type="fig"}A), and at 48 hpi, anti-GFP antibody was used to precipitate TRAF6-GFP. We were only able to pull down LGTV NS3 with TRAF6-GFP ([Figure 1](#fig1){ref-type="fig"}D). These results suggest that LGTV NS3 and TRAF6 proteins interact during TBFV infection.

To identify the structural and functional requirements of the LGTV NS3pro-TRAF6 interaction, we engineered epitope-tagged recombinant NS3 constructs and compared their interaction with wild-type (WT) TRAF6 using a co-affinity purification (coAP) technique based on biotin-streptavidin binding ([@bib39]). NS3 protease activity is dependent on a non-covalent interaction with NS2B ([@bib11], [@bib12]). To express NS3 with a functional protease domain, we fused NS2B and NS3 together in a single open reading frame, as occurs in the polyprotein (NS2B/3). Once translated within the cell, the NS2B/3 polyprotein undergoes autocatalytic cleavage, freeing NS2B from NS3 ([@bib2], [@bib23]). This cleavage event is detected on immunoblot as a doublet, with NS2B/3 having a larger molecular weight than NS3 alone. As a confirmation of the interaction detected during virus infection, TRAF6 precipitated both full-length LGTV NS2B/3 and truncated LGTV NS2B/3pro when expressed in HEK293 cells ([Figure 1](#fig1){ref-type="fig"}E). Next, we engineered the following two constructs to directly test the requirement of NS3 protease activity for NS3pro binding to TRAF6: (1) an LGTV NS3pro construct that lacks NS2B and thus has no enzymatic activity and (2) a mutated LGTV NS3 serine 138 to alanine, which disrupts the catalytic triad needed for protease activity ([@bib32]). We found in both instances that NS3 was able to interact with TRAF6 regardless of a functional NS3 protease ([Figures 1](#fig1){ref-type="fig"}E, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E). Finally, LGTV NS5, the major interferon (IFN) antagonist of TBFVs ([@bib3]), was not precipitated with TRAF6 and served as a negative control, whereas TRAF6 forms a strong homomeric complex with alternatively tagged TRAF6 as previously reported ([@bib28]) ([Figure 1](#fig1){ref-type="fig"}E). These results show that TRAF6 specifically interacts with the protease domain of LGTV NS3 and that the protease activity of NS3 is not required for this interaction.

TBFVs Use TRAF6 for Optimal Replication {#sec2.2}
---------------------------------------

To assess the role of TRAF6 in TBFV replication, we infected WT and TRAF6^−/−^ murine embryonic fibroblasts (MEFs) with LGTV. In contrast to what we predicted, we found that TRAF6 is needed for optimal LGTV replication ([Figures 2](#fig2){ref-type="fig"}A--2C and [S2](#mmc1){ref-type="supplementary-material"}A). There was up to a 14.2-fold reduction in the release of infectious virions from TRAF6-deficient cells compared with cells expressing TRAF6 ([Figure 2](#fig2){ref-type="fig"}B). Moreover, NS3 and E proteins were readily detectable in LGTV-infected WT MEFs compared with TRAF6^−/−^ MEFs ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}A). We observed a similar reduction in LGTV replication when we infected CRISPR/Cas9-generated TRAF6^−/−^ HEK293 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B). To demonstrate that the reduction in LGTV titers was due to a lack of TRAF6, we complemented TRAF6^−/−^ HEK293 cells with human TRAF6-GFP and found that LGTV titers were restored to WT levels ([Figure 2](#fig2){ref-type="fig"}D). In addition, we functionally depleted HEK293 cells of TRAF6 using a commercially available TRAF6 peptide inhibitor ([@bib18]) and by overexpressing a TRAF6 construct with a mutation in the ligase catalytic site ([@bib29]). In both cases, LGTV replication was significantly diminished to levels similar to TRAF6^−/−^ cells ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2E). Conversely, LGTV replication was similar between TRAF6-GFP overexpressing cells and control cells, suggesting that endogenous TRAF6 is sufficient for the observed proviral effect during LGTV infection ([Figures 2](#fig2){ref-type="fig"}D, [S2](#mmc1){ref-type="supplementary-material"}D, and S2E). Furthermore, we infected TRAF6^−/−^ cells with the highly virulent TBEV and KFDV and observed similar trends as with LGTV ([Figures 2](#fig2){ref-type="fig"}E, 2F, [S2](#mmc1){ref-type="supplementary-material"}F, and S2G). There was a 9.9-fold reduction in TBEV and 8.6-fold reduction in KFDV titers in TRAF6^−/−^ MEFs at 24 hpi ([Figures 2](#fig2){ref-type="fig"}E and 2F), suggesting that TRAF6 promotes the replication of TBFVs regardless of their virulence.Figure 2TRAF6 Is a Proviral Factor for TBFVs(A) Representative images of confocal microscopy of LGTV-infected WT or TRAF6^−/−^ MEFs. MEFs were infected at an MOI of 1 and were processed at 24 hpi. Cells were immunostained with anti-E (green) and anti-NS3 (red) antibodies. Nuclei were stained with DAPI (blue); scale bar (white solid line), 200 μM.(B) Titration of infectious particles in the supernatant from WT or TRAF6^−/−^ MEFs infected with LGTV (MOI of 0.1) for indicated times (h). Viral titers were determined by immunofocus assay (left y axis). IFN-β protein in supernatants from infected cells was quantitated by ELISA and is represented by a column graph (right y axis). Results are representative of three or more independent experiments performed in triplicate and plotted as mean ± SEM. ns, not significant; \*p \< 0.05, \*\*\*p \< 0.001.(C) Immunoblot analysis of whole-cell extracts from WT or TRAF6^−/−^ MEFs infected with LGTV (MOI 0.1) for indicated times (h). Blots were probed with antibodies to LGTV NS3, LGTV E, IFIT2, IFIT3, TRAF6, and β-actin. Results representative of three or more independent experiments. See [Figure S2](#mmc1){ref-type="supplementary-material"}A for longer exposures of LGTV NS3 and LGTV E.(D) Titration of infectious particles in the supernatant from WT or TRAF6^−/−^ HEK293 cells expressing either GFP or TRAF6-GFP infected with LGTV (MOI of 0.1) at 24 hpi. Viral titers were determined by plaque assay. Whole-cell extracts from the infected cells were analyzed by immunoblot using GFP, TRAF6, and β-actin antibodies. Data are average of three independent experiments performed in triplicate and plotted as mean ± SEM. ns, not significant; \*\*\*\*p \< 0.0001.(E--G) Titration of infectious particles in the supernatant from WT or TRAF6^−/−^ MEFs infected with TBEV (E), KFDV (F), or WNV (G) (MOI of 0.1) for indicated times (h). Viral titers were determined by plaque assay. Data are average of three independent experiments performed in triplicate and plotted as mean ± SEM. ns, not significant; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.(H) Representative images of confocal microscopy of KUNV-infected WT or TRAF6^−/−^ MEFs. MEFs were infected at an MOI of 1 and were processed at 24 hpi. Cells were immunostained with anti-NS3 (green) antibodies. Nuclei were stained with DAPI (blue); scale bar (white solid line), 100 μM.(I) Titration of infectious particles in the supernatant from WT or TRAF6^−/−^ MEFs infected with KUNV (MOI of 0.1) for indicated times (h). Viral titers were determined by plaque assay. Data are representative of three or more independent experiments performed in triplicate and plotted as mean ± SEM. ns, not significant; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.(J) Immunoblot analysis of whole-cell extracts from WT or TRAF6^−/−^ MEFs infected with KUNV (MOI 0.1) for indicated times (h). Blots were probed with antibodies to WNV NS3, TRAF6, and β-actin. Results representative of three or more independent experiments.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To assess the interplay between TBFV replication, TRAF6, and IFN production, we quantified IFN-β in the supernatant of LGTV-infected TRAF6^−/−^ MEFs. We were only able to detect IFN-β (20.6 pg/mL) at 72 hpi in the supernatant from WT MEFs. IFN-β remained undetectable in the supernatants from TRAF6^−/−^ MEFs throughout the course of infection ([Figure 2](#fig2){ref-type="fig"}B). Moreover, the levels of IFN-β directly correlated with the expression of the IFN-stimulated genes, IFIT2 and IFIT3, as detected by immunoblot of the cell lysates ([Figure 2](#fig2){ref-type="fig"}C). These data indicate that the attenuation of LGTV replication in TRAF6^−/−^ MEFs is not due to increased IFN production.

To compare the impact of TRAF6 on TBFVs to MBFVs, we infected TRAF6^−/−^ MEFs with WNV and KUNV. We observed a striking difference between the MBFVs and TBFVs ([Figures 2](#fig2){ref-type="fig"}G--2J). The replication of WNV and KUNV was enhanced in the absence of TRAF6, both reaching higher viral titers in MEFs deficient in TRAF6 compared with WT ([Figures 2](#fig2){ref-type="fig"}G and 2I). Infection of TRAF6^−/−^ MEFs resulted in up to 8.9-fold increase in KUNV titers and an increase in NS3 production compared with WT MEFs ([Figures 2](#fig2){ref-type="fig"}H--2J). Taken together, these results show that TRAF6 specifically supports TBFV replication, which is distinctly different from its antiviral role in MBFV infection.

Mutation of TBM2 Prevents TRAF6-NS3pro Interaction and Reduces Accumulation of the Mature Protease {#sec2.3}
--------------------------------------------------------------------------------------------------

Previous studies have shown that mutation of the anchor glutamic acid residue in a TBM to an alanine disrupts TRAF6 binding ([@bib40], [@bib46]). To determine which TBM(s) in LGTV NS3pro interacts with TRAF6, we mutated the acidic amino acid in each TBM of LGTV NS2B/3pro to alanine. We tested the ability of each mutant to bind TRAF6 by coAP assay. We found that a D19A mutation in TBM1 had no effect on binding, whereas an E117A mutation in TBM2 resulted in a significant decrease in binding to TRAF6 ([Figure 3](#fig3){ref-type="fig"}A). E117A mutation also diminished the TRAF6 interaction to NS2B/3pro_D19A mutant ([Figure 3](#fig3){ref-type="fig"}A). Quantification of immunoblots using densitometry showed a 56.1% and a 58.6% decrease in pull down of TRAF6 by LGTV NS2B/3pro_E117A and LGTV NS2B/3pro_D19A_E117A, respectively ([Figure 3](#fig3){ref-type="fig"}B).Figure 3An E117A Mutation in LGTV NS3pro Disrupts TRAF6 Binding and Mature Protease Accumulation(A) CoAP of mutant LGTV NS2B/3pro constructs with TRAF6. HEK293 cells were transfected with 2 μg of each indicated plasmid. Cell lysates were pulled down using streptavidin-conjugated beads at 24 h post-transfection, and eluted proteins were analyzed by immunoblot with indicated antibodies. Results representative of three independent experiments.(B) Quantification of TRAF6 pull-down by mutant LGTV NS2B/3pro constructs in (A). Precipitated TRAF6-GFP from three independent experiments were quantitated using ImageJ after normalization to β-actin. Data are presented as percent pull-down of TRAF6-GFP relative to NS2B/3pro WT ± SD. ns, not significant; \*\*\*p \< 0.001.(C) Immunoblot analysis of whole-cell extracts from HEK293 cells expressing mutant LGTV NS2B/3pro constructs. HEK293 cells were transfected with 2 μg of each indicated plasmid and processed 24 h post-transfection. Blots were probed with indicated antibodies. Results representative of three independent experiments.(D) Quantification of cleaved NS3pro of mutant LGTV NS2B/3pro constructs in (C). Cleaved NS3pro from three independent experiments were quantitated using ImageJ after normalization to β-actin. Data are presented as percent cleavage relative to NS2B/3pro WT ± SD. ns, not significant; \*\*\*\*p \< 0.0001.(E) The modeled structure of the complex of the LGTV NS3pro TBM2 (colored in magenta) with the C-terminal MATH domain of TRAF6 (colored in cyan). Dashed lines indicate dual hydrogen bonds between the omega oxygen atom of E117 of NS3 and the backbone amide N-H groups of L457 and A458 of TRAF6.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

After performing coAP assays with LGTV NS2B/3pro mutants, we noticed that constructs with an E117A mutation had reduced levels of the cleaved, mature form of NS2B/3pro ([Figure 3](#fig3){ref-type="fig"}A). The disappearance of NS3pro could be due to a structural change in protein stability, or a functional change in protease activity leading to decreased autoproteolytic cleavage. To confirm that the lower-molecular-weight protein was produced by autocatalytic cleavage, we inactivated the protease by an additional S138A mutation, which resulted in a total loss of the lower molecular weight band ([Figure 3](#fig3){ref-type="fig"}C). Quantification of immunoblots by densitometry showed that the E117A mutation reduced mature NS3pro accumulation by 82.5% compared with the WT or D19A proteins ([Figure 3](#fig3){ref-type="fig"}D).

To further assess the TRAF6-NS3pro interaction at TBM2, we modeled the interaction of LGTV NS3pro and TRAF6 *in silico*. The crystal structures of TRAF6 and substrate ligands have been solved for several complexes and demonstrate a specific pattern of hydrogen bonding between the MATH domain of TRAF6 and the TBM of an interacting protein ([@bib36], [@bib44]). Indeed, it was from these structures and through mutational analysis that the canonical TBM was determined. We set out to use these data to evaluate the structural interaction of LGTV NS3pro and TRAF6 through TBM2. Unfortunately, no crystal structure exists for any TBFV NS3. So, we began by first generating an LGTV NS3pro model using homology modeling with Murray Valley encephalitis virus NS3 crystal structure as a template ([@bib1]) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). TBM2 of LGTV NS3pro was found to form a beta strand that is situated on the surface of the protein ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Next, we modeled the structure of the complex of the TBM2 of LGTV NS3pro with the MATH domain of TRAF6 ([Figure 3](#fig3){ref-type="fig"}E). The negatively charged omega oxygen atom of E117 of LGTV NS3 formed dual hydrogen bonds with the backbone amide N-H groups of L457 and A458 of TRAF6 ([Figure 3](#fig3){ref-type="fig"}E). The intermolecular interaction energies between E117 of LGTV NS3pro and their interacting protein partners in TRAF6 were calculated at the MP2/6-311++G\*\* level using the supermolecular approach with the Gaussian 09 package ([@bib13]) as described previously ([@bib26]). The resulting interaction energies in both the gas phase (ΔE^gas^) and the solution phase (ΔE^solution^) are listed in [Table 1](#tbl1){ref-type="table"}. For comparison, the calculated intermolecular interaction energies between the mutated A117 residue of LGTV NS3 and their interacting protein partners are also listed. In the NS3pro_E117A mutant, the dual hydrogen bonds are lost, which results in a binding energy loss of 3.44 kcal/mol in the solution phase. Overall, both *in silico* and biological data support the conclusion that an E117A mutation in NS3pro interferes with TRAF6 binding. The unexpected result of the E117A mutation on the abundance of mature NS3pro warrants further studies into the potential effect(s) of TRAF6 on NS3pro structure and protease function.Table 1Intermolecular Interaction Energies between E117 or A117 of LGTV NS3pro and the Backbone Amide N-H Groups of L457 and A458 of TRAF6Intermolecular PairΔE^gas^ (kcal/mol)ΔE^solution^ (kcal/mol)E117 of NS3 \-\-- L457, A458 of TRAF6−19.23−3.60A117 of NS3 \-\-- L457, A458 of TRAF6−0.09−0.16[^2][^3]

An LGTV Mutant Virus Containing the E117A Mutation Exhibits a Small Plaque Phenotype and Is Attenuated In Vitro {#sec2.4}
---------------------------------------------------------------------------------------------------------------

To test the impact of an E117A mutation on the ability of LGTV to replicate, we created the mutation in the LGTV infectious clone. The plaque-forming ability of the LGTV NS3_E117A mutant was noticeably reduced compared with that of the LGTV following transfection of equal amounts of *in vitro* transcribed mRNA ([Figure 4](#fig4){ref-type="fig"}A). Also, recovered LGTV NS3_E117A foci were reduced by 81.8% compared with recovered WT and NS3_D19A LGTV ([Figure 4](#fig4){ref-type="fig"}B). Consistently, we observed reduced replication of LGTV NS3_E117A in HEK293 cells compared with LGTV and LGTV NS3_D19A by immunofluorescent microscopy, immunofocus assay, and immunoblotting ([Figures 4](#fig4){ref-type="fig"}C--4E). There was up to a 17.4-fold reduction in the release of infectious virions from LGTV NS3_E117A-infected cells compared with cells infected with LGTV or LGTV NS3_D19A ([Figure 3](#fig3){ref-type="fig"}D). To test if LGTV NS3_E117A attenuation is due to an impaired ability to co-opt TRAF6 during replication, we infected WT and TRAF6^−/−^ MEFs with LGTV NS3_E117A and LGTV. Similar to observations made with HEK293 cells, replication of LGTV NS3_E117A was reduced by 7.8-fold compared with LGTV in WT MEFs ([Figure 4](#fig4){ref-type="fig"}F). Alternatively, the attenuation of LGTV NS3_E117A was lost in TRAF6^−/−^ MEFs; there was no statistical difference between titers from LGTV NS3_E117A and LGTV-infected TRAF6^−/−^ MEFs ([Figure 4](#fig4){ref-type="fig"}F). Taken together, these data suggest that an E117A mutation in NS3 impairs LGTV replication and that this attenuation is dependent on TRAF6.Figure 4LGTV NS3 E117A Mutant Virus Is Attenuated *In Vitro*(A) Representative images of confocal microscopy of HEK293 cells transfected with either LGTV or LGTV_E117A *in vitro*-transcribed genomic RNA. Cells were processed at 72 h post-transfection and immunostained with anti-NS3 (red) and anti-E (green) antibodies. Nuclei were stained with DAPI (blue); scale bar (white solid line), 50 μM.(B) Measurement of viral foci in Vero cells infected with recovered LGTV, LGTV NS3_D19A, or LGTV NS3_E117A. The area (mm^2^) of individual foci formed by each virus was calculated using ImageJ. Representative foci of each virus are presented below the column graph. Data are average of three independent experiments performed in triplicate and plotted as mean ± SEM. ns, not significant; \*\*p \< 0.01; \*\*\*p \< 0.001.(C) Representative images of confocal microscopy of HEK293 cells infected with LGTV, LGTV NS3_D19A, or LGTV NS3_E117A. HEK293 cells were infected at an MOI of 0.1 and were processed at 24 hpi. Cells were immunostained with anti-E (green) and anti-NS3 (red) antibodies. Nuclei were stained with DAPI (blue); scale bar (white solid line), 200 μM.(D) Titration of infectious particles in the supernatant from HEK293 cells infected with LGTV, LGTV NS3_D19A, or LGTV NS3_E117A (MOI of 0.1) for indicated times (h). Viral titers were determined by immunofocus assay. Data are representative of three or more independent experiments performed in triplicate and plotted as mean ± SEM. ns, not significant; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001.(E) Immunoblot analysis of whole-cell extracts from HEK293 cells infected with LGTV, LGTV NS3_D19A, or LGTV NS3_E117A (MOI 0.1) for indicated times (h). Blots were probed with antibodies to LGTV NS3, LGTV E, TRAF6, and β-actin. Results representative of three or more independent experiments.(F) Titration of infectious particles in the supernatant from WT or TRAF6^−/−^ MEFs infected with LGTV or LGTV NS3_E117A (MOI of 0.1) at 24 hpi. Viral titers were determined by plaque assay. Data are representative of three independent experiments performed in triplicate and plotted as mean ± SEM. ns, not significant; \*\*\*p \< 0.001.

Discussion {#sec3}
==========

In this study, we provide evidence that TRAF6 plays an unexpected proviral role in TBFV replication. We found that TRAF6 interacts with TBFV NS3pro in a sequence-dependent manner and that targeted inhibition of the complex formation leads to virus attenuation.

We have identified a non-canonical TBM that appears to be conserved among closely related TBFVs and is not present in MBFVs ([Figure 1](#fig1){ref-type="fig"}A). A physical interaction between flavivirus NS3 and TRAF6 has not been previously reported. It has been shown that NS3 from classical swine fever virus (CSFV), a pestivirus, binds and degrades TRAF6 to prevent activation of NF-κB signaling pathways during infection ([@bib25]). Although CSFV is a member of the Flaviviridae, it differs from flaviviruses in several ways. (1) The genome of CSFV is composed of a different number and set of genes than flaviviruses ([@bib47]); (2) CSFV NS3 requires NS4A, not NS2B, as an essential cofactor of protease activity ([@bib38]); (3) CSFV is not transmitted by arthropod vectors; and (4) CSFV does not cause disease in humans ([@bib5]).

TRAF6 is conventionally associated with host innate immune protection because of its pivotal role in IL-1/TLR and RIG-I signaling ([@bib19], [@bib45]). It was previously shown that prototypical RNA viruses replicate better and are more cytopathic in TRAF6-deficient cells because of a mitigated IFN response ([@bib20], [@bib45]). Studies examining the role of TRAF6 during flavivirus infection have been limited to MBFVs. DENV and Japanese encephalitis virus (JEV) have been found to up-regulate cellular miR-146a to decrease expression and signaling of TRAF6; suppression of TRAF6 leads to decreased NF-κB activation, Jak-STAT signaling, and IFN production, and in the case of DENV, also inhibited virus-induced autophagy ([@bib33], [@bib35], [@bib43]). The effect of TBFV NS3 binding to TRAF6 is an intriguing and unexplored question for follow-up studies, especially if TBFV NS3 binding to TRAF6 inhibits the canonical antiviral signaling role for TRAF6, while using TRAF6 to benefit virus replication.

It was unexpected when we observed better replication of TBFVs in WT MEFs compared with TRAF6^−/−^ MEFs ([Figures 2](#fig2){ref-type="fig"}A--2C, 2E, and 2F). Indeed, because our findings differ from precedent, we took multiple approaches to validate the proviral effects of TRAF6 in TBFV infection. (1) We used two independently generated TRAF6 knockout cell lines: embryonically derived TRAF6^−/−^ MEFs and CRISPR/Cas9 generated TRAF6^−/−^ HEK293 cells ([Figures 2](#fig2){ref-type="fig"}A--2C and [S2](#mmc1){ref-type="supplementary-material"}B). (2) We functionally depleted WT cells of TRAF6 by overexpressing an enzymatically inactive TRAF6 mutant ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). (3) We treated WT cells with a TRAF6 inhibitor peptide ([Figure S2](#mmc1){ref-type="supplementary-material"}C). (4) We mutated TBM2 within a TBFV genome ([Figure 4](#fig4){ref-type="fig"}). Under all these conditions, we consistently saw TBFV attenuation. Furthermore, the phenotype could be rescued by the expression of TRAF6 ([Figure 2](#fig2){ref-type="fig"}D).

When we assessed MBFV replication in our TRAF6^−/−^ MEFs, using WNV and KUNV, we observed a reciprocal phenotype than what was seen with TBFVs. MBFV replication was enhanced in the absence of TRAF6, similar to previous DENV and JEV studies ([Figures 2](#fig2){ref-type="fig"}G--2J). As predicted from our sequence analysis ([Figure 1](#fig1){ref-type="fig"}A), KUNV NS3 did not interact with TRAF6 during infection ([Figure 1](#fig1){ref-type="fig"}D). Furthermore, we saw better LGTV replication in WT MEFs compared with TRAF6^−/−^ MEFs despite higher IFN-β production ([Figure 2](#fig2){ref-type="fig"}B). Taken all together, our findings demonstrate that the proviral function of TRAF6 is specific to TBFVs.

An E117A mutation in TBM2 of NS3pro revealed that interaction with TRAF6 is needed for the accumulation of the mature processed form of the protease. Note that TRAF6-NS3pro binding is not essential for protein function. This allowed us to design and recover mutant LGTV NS3_E117A, which was attenuated to similar levels seen with WT LGTV in TRAF6-deficient cells ([Figures 4](#fig4){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B). We failed to precipitate TRAF6 from LGTV NS3_E117A-infected cells (data not shown); these experiments were confounded by reduced viral protein levels associated with the LGTV NS3_E117A ([Figure 4](#fig4){ref-type="fig"}E). LGTV NS3_E117A attenuation is most likely a result of decreased interaction with TRAF6 because the difference between mutant and WT virus is lost in TRAF6^−/−^ MEFs ([Figure 4](#fig4){ref-type="fig"}F). In contrast, overexpression of TRAF6 did not enhance virus production, suggesting that the endogenous level of TRAF6 is sufficient for optimal virus replication ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}D), albeit viral protein levels were modestly elevated ([Figure S2](#mmc1){ref-type="supplementary-material"}E).

We are currently evaluating how TRAF6 benefits TBFV replication, looking specifically for structural changes to NS3pro when complexed with TRAF6 and changes to overall protease activity. TRAF6 is an E3 ubiquitin ligase and performs its normal physiological function by ubiquitinating itself and substrate proteins ([@bib41]). TBFV NS3pro may be modified by TRAF6-mediated non-degradative ubiquitination; this hypothesis is supported by our observation of LGTV attenuation in cells overexpressing an enzymatically inactive TRAF6 ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). It has previously been shown that K27-linked ubiquitination of DENV NS3 facilitates NS2B recruitment and NS2B/3pro complex formation; the ligase has yet to be identified ([@bib23]).

The flavivirus NS3 is an attractive therapeutic target because it is essential for virus replication and has well-characterized enzymatic functions ([@bib21]). Substantial effort and resources have been put into the design of inhibitors of NS3pro activity, but there has only been limited success and no compound has reached the clinical trial stage. It has been challenging to develop NS3pro inhibitors because the active site is shallow and highly charged ([@bib24]). We propose that the TRAF6-NS3pro interaction may serve as an antiviral target. Specific disruption of the TRAF6-NS3pro complex, as demonstrated by our use of a TRAF6 inhibitor peptide in this study ([Figure S2](#mmc1){ref-type="supplementary-material"}C), could indirectly inhibit NS3 function and be accomplished without having to overcome the multiple obstacles that are associated with development of compounds that directly inactivate NS3. Likewise, we speculate that the attenuation and small plaque phenotype of the E117A mutant virus *in vitro* may result in impaired *in vivo* pathogenesis as reported for other mutant flaviviruses, including LGTV ([@bib4], [@bib10], [@bib16], [@bib34]).

Overall, our study demonstrates that specific flavivirus therapeutic targets may be identified by first understanding how viruses and host cell proteins interact. By identifying a specific interaction between TRAF6 and TBFV NS3pro, we revealed a mechanism used by viruses to co-opt host cell antiviral molecules for viral gain.

Limitations of the Study {#sec3.1}
------------------------

There are still many issues to be investigated regarding the role of TRAF6 in TBEV infection, including (1) the exact mechanism as to how a TRAF6-NS3pro interaction affects mature NS3pro accumulation and ultimately virus replication; TRAF6, a E3 ubiquitin ligase, may ubiquitinate NS3 directly or act as a scaffold protein bring together other host or viral proteins; and (2) the importance of TRAF6 in TBFV pathogenesis in primary cells, including dendritic cells and neurons, and within *in vivo* models. (3) Our investigations only examine the proviral role of TRAF6 in TBFV infection; however, TBFV antagonism of the antiviral activity of TRAF6 likely contributes to the overall success of TBFVs to cause disease.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S3
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[^1]: Lead Contact

[^2]: ΔE^gas^ and ΔE^solution^ represent intermolecular interaction energy in vacuum and in aqueous solution, respectively. Intermolecular interaction energies were calculated with the supermolecular approach at the MP2/6-311++G\*\* level.

[^3]: See also [Figure S3](#mmc1){ref-type="supplementary-material"}.
